Editorial
Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma
Abstract
Despite falling incidence rates, squamous cell carcinoma of the oesophagus (OSCC) remains a common cancer globally; in 2012 an estimated 398,000 OSCC diagnoses were made worldwide (1-3).
